Competition is close for top positions
Pharmaceutical companies continue to inch forward in addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index. Pfizer moves into the top five. GSK retains its number one position, yet only slightly ahead of Novartis.
1 | GlaxoSmithKline plc |
0
1
2
3
4
5
|
4.23 | |
GlaxoSmithKline plcRead more |
||||
2 | Novartis AG |
0
1
2
3
4
5
|
4.18 | |
Novartis AGRead more |
||||
3 | Johnson & Johnson |
0
1
2
3
4
5
|
3.76 | |
Johnson & JohnsonRead more |
||||
4 | Pfizer Inc. |
0
1
2
3
4
5
|
3.65 | |
Pfizer Inc.Read more |
||||
5 | Sanofi |
0
1
2
3
4
5
|
3.47 | |
SanofiRead more |
||||
6 | Takeda Pharmaceutical Co. Ltd. |
0
1
2
3
4
5
|
3.31 | |
Takeda Pharmaceutical Co. Ltd.Read more |
||||
7 | AstraZeneca plc |
0
1
2
3
4
5
|
3.30 | |
AstraZeneca plcRead more |
||||
8 | Merck KGaA (Merck) |
0
1
2
3
4
5
|
3.09 | |
Merck KGaA (Merck)Read more |
||||
9 | Roche Holding AG |
0
1
2
3
4
5
|
3.07 | |
Roche Holding AGRead more |
||||
10 | Novo Nordisk A/S |
0
1
2
3
4
5
|
2.96 | |
Novo Nordisk A/SRead more |
||||
11 | Eisai Co. Ltd. |
0
1
2
3
4
5
|
2.87 | |
Eisai Co. Ltd.Read more |
||||
12 | Boehringer Ingelheim GmbH |
0
1
2
3
4
5
|
2.84 | |
Boehringer Ingelheim GmbHRead more |
||||
13 | Bayer AG |
0
1
2
3
4
5
|
2.63 | |
Bayer AGRead more |
||||
14 | Astellas Pharma Inc. |
0
1
2
3
4
5
|
2.33 | |
Astellas Pharma Inc.Read more |
||||
14 | Gilead Sciences Inc. |
0
1
2
3
4
5
|
2.33 | |
Gilead Sciences Inc.Read more |
||||
15 | Merck & Co., Inc. (MSD) |
0
1
2
3
4
5
|
1.88 | |
Merck & Co., Inc. (MSD)Read more |
||||
16 | Daiichi Sankyo Co. Ltd. |
0
1
2
3
4
5
|
1.80 | |
Daiichi Sankyo Co. Ltd.Read more |
||||
17 | AbbVie Inc. |
0
1
2
3
4
5
|
1.73 | |
AbbVie Inc.Read more |
||||
18 | Eli Lilly & Co. |
0
1
2
3
4
5
|
1.59 | |
Eli Lilly & Co.Read more |
||||
19 | Bristol Myers Squibb Co. |
0
1
2
3
4
5
|
1.55 | |
Bristol Myers Squibb Co.Read more |
0
1
2
3
4
5
|
The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.
Insights
-
Pfizer joins top 5
GSK retains its number one position, yet only slightly ahead of Novartis. Pfizer moves into the top five. Johnson & Johnson and Sanofi complete the top five companies. Eight of the top ten companies, including the leaders, are setting a new best practice of systematic access planning during R&D.
-
Leaders match actions to specific needs
Leading companies perform well across all areas of measurement, with a mature approach to managing access, addressing access to specific products. They are committed to R&D for global health priorities and specific needs of people in low- and middle- income countries.
-
Addressing access inches toward standard practice
There is progress in companies integrating access to medicine into governance structures, R&D processes, and monitoring efforts. Yet initiatives addressing access to specific products remain focused on a few products and countries.
-
2021 Index focuses on core role for pharma
Achieving the SDGs and UHC by 2030 means delivering health products to everyone in need. Success depends on pharma companies moving to systematically address access at all levels of the health system. The Index evaluates how companies measure up to their core role for improving access.